<Back to current news

Press Release - for immediate release

29 September 2008

AstraZeneca present on Proven Strategies for Process Development & Optimisation at Bioprocessing Conference

Dr Kristina Lindgren from AstraZeneca presented during the 'Proven Strategies for Process Development & Optimisation' session at last week's Bioprocessing Conference, in Anaheim, CA.

Her talk was entitled "Automation of GS-CHO Cell Line Development Together with Pool Strategy Enables Rapid and Cost Efficient Biopharmaceutical Development".

She presented on cell line development using TAP's Cello™ robotic system and a transfection pool strategy for delivery of early pre-clinical material was performed in parallel to shorten timelines in biopharmaceutical development. Pre-clinical material was harvested within 10 weeks from a 20L-bioreactor containing ~3g/L. A clonal cell line producing 5g/L in 100ml fed-batch shake flask culture was achieved using the same expression plasmid.

TAP's Cello system automates mammalian cell culture in plates, and enables efficient selection of optimal clones to provide cell lines for biologics. It cultures multiple clones in parallel, from seeding through expansion and sub-cloning. The system provides the throughput and capacity needed to support several projects running in parallel, with minimal operator involvement. Cello cultures both adherent and non-adherent cell lines, growing in 384, 96, 24 and 6-well plates.

For further information, please contact:

York Way, Royston, Hertfordshire, SG8 5WY, UK
Tel: +44 1763 227200 Fax: +44 1763 227201

For more information on Cello, visit:

Cello - system overview

<Back to current news